Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in sustainable pharmaceutical manufacturing, announced that its team will attend the second annual BioLogic Summit from January 19-22, 2026, in San Diego. The summit focuses on applying machine learning and artificial intelligence to design and optimize biotherapeutics.
Quantumzyme's participation underscores its strategic commitment to staying engaged in AI-enabled enzyme engineering and protein design. The conference provides an opportunity for the company's scientific leaders to engage in technical discussions, share insights, and explore advancements that align with its internal development efforts and its proposed evolution to Quantum Genesis AI Corp., pending FINRA approval.
The BioLogic Summit caters to hybrid scientists who integrate experimental and computational methods, a profile that matches the Quantumzyme team. By attending, the company aims to stay current on developments in generative AI, lab-in-the-loop optimization, and structure-based design. These insights are intended to advance the company's platform and ensure alignment with relevant methodologies.
“Innovation doesn’t happen in isolation. Being present and actively engaging with the brightest minds in our field is essential to driving our mission forward,” stated Naveen Kulkarni, CEO of Quantumzyme Corp. “The BioLogic Summit provides a valuable venue for our team to connect with individuals and organizations contributing to the future of AI in biologics. Our goal is to learn from the latest research, understand emerging challenges, and explore potential collaborations that may support greener and more efficient manufacturing approaches across the pharmaceutical industry.”
For more information, visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.
Quantumzyme Corp. is a biotransformation company focused on sustainable enzyme-based solutions for pharmaceutical manufacturing. It applies quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to develop biocatalysts that enhance efficiency, reduce waste, and support environmentally responsible production. By integrating computational modeling with laboratory validation, Quantumzyme aims to deliver scalable, cost-effective biocatalysis solutions.
This press release contains forward-looking statements subject to risks and uncertainties. The company undertakes no obligation to update these statements.
